July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Xen 45 surgical results: retrospective comparison of primary XEN implantation, filtering bleb needling and open filtering bleb revision
Author Affiliations & Notes
  • Stefan Steiner
    Department of Ophthalmology and Optometry, Medical University of Vienna, Hochwolkersdorf, Austria
  • Hemma Resch
    Department of Ophthalmology and Optometry, Medical University of Vienna, Hochwolkersdorf, Austria
  • Barbara Kiss
    Department of Ophthalmology and Optometry, Medical University of Vienna, Hochwolkersdorf, Austria
  • Clemens Vass
    Department of Ophthalmology and Optometry, Medical University of Vienna, Hochwolkersdorf, Austria
  • Footnotes
    Commercial Relationships   Stefan Steiner, None; Hemma Resch, None; Barbara Kiss, None; Clemens Vass, Allergan (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3738. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stefan Steiner, Hemma Resch, Barbara Kiss, Clemens Vass; Xen 45 surgical results: retrospective comparison of primary XEN implantation, filtering bleb needling and open filtering bleb revision. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3738.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Patients who underwent Xen 45 surgery frequently require needling or revision surgery. To compare intraocular pressure (IOP), glaucoma medication (GM), complications and reinterventions of XEN implantation, filtering bleb needling (FBN) and open filtering bleb revision (OFBR).

Methods : This is a retrospective, observational study of 269 eyes who underwent Xen surgery. Following groups were formed for data evaluation: 1) Primary Xen surgery until last follow up (FU), 2) Primary Xen surgery until first needling/revision/surgery (NRS), 3) FBN until next NRS, 4) OFBR until next NRS. Main outcome measures were IOP, number of GM, NRS and complications.

Results : IOP in Group 1 was lowered from 23.3 (±8.3) mmHg to 15.6 (±6.3) mmHg, number of GM was reduced from 3.1 (±1.0) to 1.1 (±1.3) after a mean FU of 9.4 (±7.2) months. Group 2: IOP 23.3 (±8.3) mmHg to 18.1 (±8.5) mmHg, GM 3.1(±1.0) to 1.4 (±1.4) after a mean FU of 6.9 (±6.0) months. Group 3: IOP 23.7 (±7.6) mmHg to 18.3 (±7.3) mmHg, GM 2.0 (±1.4) to 1.8 (±1.3) after a mean FU of 6.7 (±6.5) months. Group 4: IOP 21.6 (±6.3) mmHg to 16.4 (±6.3) mmHg, GM 2.4 (±1.1) to 1.0 (±1.4) after a mean FU of 6.0 (±4.2) months. IOP and number of GM over time are shown in Figure 1 and 2. FBN and OFBR procedure was performed in 47 (17.5%) and 71 (26.4%) eyes after a mean interval of 3.1 (±4.3) and 7.9 (±5.0) months. An additional intervention was required less frequently in group 4 (8.5%) compared to group 2 (36.4%, p<0.001) and group 3 (42.6%, p<0.001) while no significant difference was observed between Group 2 and Group 3 (Chi-Square-Test). IOP reduction and IOP at last FU was not significantly different between all groups (Anova Tukey Post-hoc-test). GM at last FU was significantly lower in Group 4 compared to Group 3 (p=0.006) and Group 2 (p=0.025) (Wilcoxon-Mann-Whitney U-Test, p values with Shaffer correction). Ocular hypotony, anterior chamber reduction and choroidal effusion all occurred significantly (p<0.05) less often in group 3 (6.4%, 0.0%, 0,0%) and group 4 (15.5%, 1,4%, 1,4%) compared to group 2 (28.3%, 9.7%, 14.1%) (Chi-Square).

Conclusions : Xen surgery is a safe and effective IOP and GM lowering method in glaucoma patients. A better safety, fewer secondary interventions and a tendency towards better IOP control was found for open filtering bleb revision as compared to primary XEN implantation and needling.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×